10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Swiss drugmaker Santhera Pharmaceuticals has had its marketing authorization application (MAA) accepted for Puldysa (idebenone) to treat respiratory dysfunction in patients with Duchenne muscular dystrophy (DMD) who are not using glucocorticoids. 25 June 2019
UK-based C4X Discovery Holdings saw its shares climb 4.55% to 52.80 pence, after announcing a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. 25 June 2019
Europe's biggest privately-held biotech BioNTech has been in the news recently, with reports the company could be about to raise just shy of a billion dollars in a US listing. 25 June 2019
The US Food and Drug Administration has issued a priority review voucher (PRV) to rare disease specialist AveXis, part of Swiss pharma giant Novartis. 25 June 2019
USA-based antibacterial products developer Entasis Therapeutics has announced the appointment of David Meek, currently chief executive of French pharma company Ipsen, as chairman of the board of directors, effective immediately. 25 June 2019
Positive Phase II results on the first topical gene therapy sent a US biotech company’s share price up by 27% in Monday morning’s trading. 24 June 2019
The US Food and Drug Administration has lifted the partial clinical hold placed on CANOVA (M13-494) in March this year, a Phase III trial evaluating venetoclax (trade named Venclexta and Venclyxto) for the investigational treatment of relapsed/refractory multiple myeloma. 24 June 2019
Bristol-Myers Squibb has announced that, to help proceed its $74 billion acquisition of biotech major Celgene, it would sell one of the latter’s top-selling drugs, Otezla (apremilast). 24 June 2019
New Jersey, USA-based drugmaker Bristol-Myers Squibb has announced a Phase III trial miss for Opdivo (nivolumab), with topline data showing the study did not meet its primary endpoint of overall survival (OS). 24 June 2019
In a filing with the US Securities and Exchange Commission (SEC), US biotech Exelixis has said it was informed last week by its collaboration partner Genentech, a US subsidiary of the Swiss pharma giant Roche, that the IMspire170 had failed to achieve pre-set goals. 24 June 2019
Some eight months after gaining marketing clearance for the drug in the USA, and an April advisory committee recommendation in Europe, US pharma giant Pfizer has now also won approval for Talzenna (talazoparib) in the European Union. 24 June 2019
The healthcare industry is at an inflection point with the market now preparing for more cell and gene therapies to be approved, writes Ana Stojanovska, vice president of Commercial Consulting at Xcenda, in an Expert View piece. 21 June 2019
For Belgium-based drugmaker UCB, EULAR 2019 came at a good time to shed further new light on bimekizumab – which the company itself is billing as its pipeline molecule – in a couple of the indications in which it is showing significant promise. 21 June 2019
The US cost-effectiveness group Institute for Clinical and Economic Review (ICER) yesterday released a Final Evidence Report assessing the comparative clinical effectiveness and value of Swiss pharma giant Novartis’ Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis (SPMS). 21 June 2019
A Phase II proof-of-concept trial evaluating the investigational interleukin (IL)-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo. 21 June 2019
At its first investor day in five years, New Jersey, USA-based Merck & Co (NYSE: MRK) outlined key aspects of its clinical and commercial strategy, with chief executive Kenneth Frazier describing: “tremendous growth opportunities beyond Keytruda.” 21 June 2019
Danish diabetes care giant Novo Nordisk announced late yesterday d that the European Commission has granted marketing authorization for Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of adolescents (≥12 years of age) and adults with hemophilia A. 21 June 2019
US gene therapy company Axovant Sciences has signed a strategic partnership with Yposkesi, a French contract development and manufacturing organization (CDMO). 20 June 2019
US protein engineering company Codexis says that Casdin Capital, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested around $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement. 20 June 2019